75 / 100

 Dr. Hang Hu| Nanomedicine | Best Researcher Award

 

👨‍🏫Profile Summary

With a background in Applied Chemistry from Hubei University and advanced degrees in Organic Chemistry and Biopharmaceutical Engineering from Huazhong University of Science and Technology, I am a dedicated researcher specializing in cancer photodynamic therapy. My academic journey includes teaching at the School of Pharmacy, Changzhou University, and contributing significantly to the field. I have co-authored over 40 SCI papers, secured 37 patents, and received recognition from esteemed journals like Materials Today Bio and ACS Applied Materials & Interfaces. My focus on developing innovative cancer treatment strategies using nanomedicines reflects my commitment to advancing the field of medical science. 🌟

🌐 Professional Profiles

Education and Academic Achievements 🎓

I earned my Bachelor’s degree in Applied Chemistry from Hubei University and pursued further studies, culminating in a Master’s degree and a Doctorate in Organic Chemistry and Biopharmaceutical Engineering from Huazhong University of Science and Technology. Throughout my academic journey, I co-authored over 40 SCI papers and secured over 30 invention patents, primarily focusing on anticancer drug delivery and cancer photodynamic therapy. Recognition from reputable journals like Materials Today Bio and ACS Applied Materials & Interfaces attests to the originality and significance of my research.

Professional Experience 🌐

After completing my Doctorate in 2018, I joined the School of Pharmacy at Changzhou University as a teacher. My research interest centered on cancer photodynamic therapy, where I contributed significantly to the development of nanomedicines for this innovative approach to cancer treatment.

Research, Innovations, and Extension Activities 🔬

My extensive involvement in research includes completing four projects, publishing in 43 SCI and SCIE indexed journals, and holding 37 patents. Additionally, I’ve participated in collaborative activities with 29 research partnerships and received recognition for my contributions.

Contribution to Photodynamic Therapy (PDT) 💡

My primary research thrust has been in enhancing Photodynamic Therapy (PDT) for cancer treatment. I’ve pioneered novel strategies using smart nanomedicines, integrating hydroxyethyl starch, polydopamine, polyethylene glycol, and protamine. By addressing challenges like tumor hypoxia and high intracellular glutathione levels, my work contributes significantly to the design of effective cancer PDT nanomedicines, promising a more targeted and less invasive treatment for cancer patients.

 

📚Top Noted Publication

Targeted Delivery of Doxorubicin to Hepatoma Cells by Lactobionic Acid-Decorated Dual Redox-Responsive Polyethylene Glycol-Doxorubicin Nanoparticles Paper Published in 2023

Reduction-responsive worm-like nanoparticles for synergistic cancer chemo-photodynamic therapy  Paper Published in 2023

Conjugates of lactobionic acid and IR820: New photosensitizers for efficient photodynamic therapy of hepatoma cells Paper Published in 2022

Mesoporous polydopamine-based multifunctional nanoparticles for enhanced cancer phototherapy  Paper Published in 2022

Polyethylene glycol-modified mesoporous polydopamine nanoparticles co-loaded with dimethylcurcumin and indocyanine green for combination therapy of castration-resistant prostate cancer Paper Published in 2022

Synthesis of Novel Pyrimidinylselenium Compounds as Acetolactate Synthase‐Inhibiting Herbicides  Paper Published in 2022

Hydroxyethyl starch based smart nanomedicine Paper Published in 2021

A comparative study of the in vitro antitumor effect of mannose‐doxorubicin conjugates with different linkers Paper Published in 2021

Hydroxyethyl starch-new indocyanine green conjugates for enhanced cancer photodynamic therapy Paper Published in 2021

pH‐Sensitive, Cerebral Vasculature‐Targeting Hydroxyethyl Starch Functionalized Nanoparticles for Improved Angiogenesis and Neurological Function Recovery in Ischemic Stroke Paper Published in 2021

A review of the effects and molecular mechanisms of dimethylcurcumin (ASC‐J9) on androgen receptor‐related diseases Paper Published in 2021

 

Hang Hu | Nanomedicine | Young Scientist Award

You May Also Like